Ralph Bertram, Hans-Theodor Naumann, Vanessa Bartsch, Wolfgang Hitzl, Martina Kinzig, Golo-Sung Haarmeyer, Matthias Baumgärtel, Arnim Geise, Dorothea Muschner, Jens Nentwich, Stefan John, Fritz Sörgel, Joerg Steinmann, Rainer Höhl
BACKGROUND: The broad-spectrum antifungal isavuconazole is administered to treat invasive aspergillosis and mucormycosis. OBJECTIVES: Isavuconazole plasma concentrations in critically ill ICU patients with or without COVID-19 and invasive fungal infection were determined, and factors for sub-therapeutic drug levels (<1 μg/mL) were evaluated. PATIENTS AND METHODS: Isavuconazole plasma levels were measured as part of therapeutic drug monitoring (TDM) in ICUs of a tertiary hospital...
September 12, 2023: Mycoses